Title: Filament Health Corp. Announces Non-Brokered Private Placement Unit Offering Led by Negev Capital
Summary:
Filament Health Corp., a clinical-stage natural psychedelic drug development company, has announced its intention to complete a non-brokered private placement for gross proceeds of up to C$2,000,000. Negev Capital, a leading venture fund in the psychedelic drug development space, will lead the offering. The funds raised will be used to advance the company’s Phase 2 methamphetamine use disorder clinical trial and for general corporate purposes.
Headings:
1. Introduction
2. Filament Health Corp. Announces Non-Brokered Private Placement Unit Offering
3. Negev Capital to Lead the Offering
4. Intended Use of Proceeds
5. Offering Details
6. Regulatory Approval
7. Applicability of Securities Laws
8. About Filament Health Corp. and Its Mission
